Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
View Patent ↗This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
1. A pharmaceutical composition comprising a compound selected from:
4-{3-chloro-6-ethoxy-2-fluoro-5-[1-([1,3]thiazolo[5,4-d]pyrimidin-7-ylamino)ethyl]phenyl}pyrrolidin-2-one;
4-{3-chloro-6-ethoxy-2-fluoro-5-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}pyrrolidin-2-one;
5-{3-chloro-6-methoxy-2-methyl-5-[(1S)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}-N,N-dimethylpyridine-2-carboxamide; and
4-chloro-N-ethyl-3′,5′-difluoro-3-methyl-6-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]biphenyl-2-carboxamide;
or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the compound is selected from:
(S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyrido[3,2-d]pyrimidin-4-yl amino)ethyl)phenyl)pyrrolidin-2-one;
(R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyrido[3,2-d] pyri mi di n-4-ylamino)ethyl)phenyl)pyrrolidin-2-one;
(S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one; and
(R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one;
or a pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition of claim 1 , wherein the compound is 4-{3-chloro-6-ethoxy-2-fluoro-5-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 3 , wherein the compound is (S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyri do[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
5. The pharmaceutical composition of claim 3 , wherein the compound is (R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyri do[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition of claim 3 , wherein the compound is (S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyri do[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 3 , wherein the compound is (R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyri do[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
8. A compound, which is 4-{3-chloro-6-ethoxy-2-fluoro-5-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , wherein the compound is (S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
10. The compound of claim 8 , wherein the compound is (R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 8 , wherein the compound is (S)-4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 8 , wherein the compound is (R)-4-(3-chloro-6-ethoxy-2-fluoro-5-((S)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.